Juno Therapeutics Inc. was a big mover last session, as the company saw its shares rise roughly 10% on the day. The stock moved up after the biopharmaceutical company got the nod from regulators to resume clinical trials of an experimental leukemia treatment. This led to solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 25.9% in the past one-month time frame.

None of the estimates for this company were revised over the past 30 days. The Zacks Consensus Estimate however moved down over the same time frame, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.

Juno Therapeutics has a Zacks Rank #4 (Sell), while its Earnings ESP is negative.

JUNO THERAPEUTC Price

JUNO THERAPEUTC Price | JUNO THERAPEUTC Quote

However, a better-ranked stock in the Med-Biomed/Gene space is CytRx Corporation , sporting a Zacks Rank #1 (Strong Buy).

Is JUNO going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>